EGFR and lung adenocarcinoma: In addition, this study provides the first clinical evidence demonstrating that savolitinib effectively reverses acquired resistance to EGFR-TKIs driven by novel METex14 skipping mutation in patients with advanced lung adenocarcinoma harboring EGFR mutations, thereby yielding long-term PFS benefits.